FASORACETAM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H16N2O2
Molecular Weight	196.2462
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C([C@H]1CCC(=O)N1)N2CCCCC2

InChI

InChIKey=GOWRRBABHQUJMX-MRVPVSSYSA-N

InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C10H16N2O2
Molecular Weight	196.2462
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9272724
Curator's Comment: description was created based on several sources, including, https://www.nootropics.eu/a-review-on-the-benefits-of-fasoracetam/

Fasoracetam is a cognition enhancer that interacts with GABA(B) receptors, stimulates neuronal ACh receptors and modulates mGlu receptors. The drug is being tested in phase III/II of clinical trials for the treatment of Attention Deficit Disorder With Hyperactivity in people with genetic disorders impacting mGlu receptors and never been approved by FDA. Fasoracetam is also being marketed in the form of capsules for research purposes aimed at investigation of cognition and memory disorders.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-B receptor 32 Target ID: CHEMBL2111463 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9424016	Antagonist 2778
Acetylcholine receptor 2 Target ID: Acetylcholine receptor Sources: http://www.ncbi.nlm.nih.gov/pubmed/10494996	Agonist 2678
Metabotropic glutamate receptors 2 Target ID: Metabotropic glutamate receptors Sources: http://www.medgenics.com/c/pipeline/	Modulator 828

Conditions

Condition	Modality	Targets	Highest Phase	Product
Attention deficit hyperactivity disorder 68 Sources: https://clinicaltrials.gov/ct2/show/NCT02777931	Primary		Phase III 656	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment.	1997 Nov 12	9424016
Comparison of pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly and young subjects.	1999	10450537
Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer.	1999 Sep	10494996

Patents

Sample Use Guides

In Vivo Use Guide

100, 200, or 400 mg twice daily as capsules for oral administration.

Route of Administration: Oral

In Vitro Use Guide

Fasoracetam (10(-7) and 10(-6) M) inhibited forskolin-stimulated cyclic AMP formation in cultured neurons of the mouse cerebral cortex. Conversely, in pertussis toxin-pretreated neurons, the drug (10(-7)-10(-5) M) significantly enhanced the forskolin-stimulated cyclic AMP formation, and this action was completely reversed by cholera toxin.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:05:17 UTC 2023` Edited by `admin` on `Fri Dec 15 16:05:17 UTC 2023`
Record UNII	42O8UF5CJB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FASORACETAM

Official Name

English

AEVI001

Code

English

NFC-1 ANHYDROUS

Code

English

(5R)-5-(PIPERIDINE-1-CARBONYL)PYRROLIDIN-2-ONE

Common Name

English

(5R)-5-(1-PIPERIDINYLCARBONYL)-2-PYRROLIDINONE

Common Name

English

LAM105 ANHYDROUS

Code

English

NFC1 ANHYDROUS

Code

English

LAM-105 ANHYDROUS

Code

English

NS-105

Code

English

(+)-1-(((R)-5-OXO-2-PYRROLIDINYL)CARBONYL)PIPERIDINE

Systematic Name

English

2-PYRROLIDINONE, 5-(1-PIPERIDINYLCARBONYL)-, (5R)-

Systematic Name

English

NS105

Code

English

fasoracetam [INN]

Common Name

English

AEVI-001

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1509